5439 results for "Psychedelics"
Psychedelics and Other Psychoplastogens for Treating Mental Illness
Frontiers in Psychiatry – October 04, 2021
Summary
Psychedelics offer remarkable hope in Medicine, demonstrating sustained therapeutic effects for mental illness, including Anxiety and depression, often after a single dose. These compounds, stemming from chemical synthesis, influence brain chemistry via neurotransmitter receptors, effectively rewiring brain circuits. In Psychiatry, they are among the most effective chemical modulators of neural plasticity identified through drug studies. This Neuroscience-backed approach marks a paradigm shift for Psychology, moving beyond symptom management toward potentially curing underlying pathophysiology. Future efforts aim to develop non-hallucinogenic versions for broader use by psychotherapists.
Abstract
Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they pr...
Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz
Psychiatric News – July 27, 2023
Summary
The FDA is fast-tracking an anti-amyloid beta vaccine for Alzheimer's disease, with early clinical trial data showing an antibody response by week 6. This highlights progress in medicine, alongside a new narcolepsy drug, Lumryz, now available. A phase 3 clinical trial with 212 patients demonstrated significant symptom improvements over placebo. Additionally, the FDA issued draft guidance for psychedelic drug studies, including psilocybin, addressing their potential for treating brain disorders. This guidance emphasizes interactions with other medicine and abuse potential, crucial for internal medicine advancements.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedel...
In naturalistic psychedelic use, group use is common and acceptable
Journal of Psychedelic Studies – June 19, 2023
Summary
Subjective negative mental health outcomes from psychedelic use are rare and not linked to solo or group modalities, according to naturalistic observation. While solo use was reportedly more common for mental health goals, natural compound pharmacology studies indicate no difference in overall mental health benefit between solo and group settings. A vast majority (95% solo, 91% group) of these experiences occur informally. This challenges clinical psychology’s traditional focus, suggesting group approaches in medicine for mental health could be equally safe and beneficial, effectively minimizing harm.
Abstract
Abstract Background and aims Most modern modalities of psychedelic-assisted psychotherapy (PAP) aim to minimize harm and maximize support by utiliz...
Authenticity and Love Drugs: Insights from Psychedelic Therapy.
AJOB neuroscience – June 16, 2025
Summary
Many view "love drugs" as unethical because the emotions they create are seen as inauthentic. However, new perspectives, drawing from psychedelic-assisted therapy, suggest that psychoactive drugs can indeed foster genuine, meaningful feelings. If these experiences lead to lasting positive change and and align with personal desires, our ethics around authenticity may need rethinking, embracing the potential for profound therapy.
Abstract
In "Prescription for Love: An Experimental Investigation of Laypeople's Relative Moral Disapproval of Love Drugs," Lantian, Boudesseul, and Cova (2...
Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity
Journal of Natural Products – March 05, 2021
Summary
A novel psilocybin analogue, 5-methylpsilocybin, exhibits potent biological activity. Its chemical synthesis involved a unique *in vitro* enzymatic phosphorylation of a tryptamine derivative, 5-methylpsilocin, utilizing a *Psilocybe cubensis* kinase. Biochemical analysis ensured high purity of this new hallucinogen. In drug studies, it showed psychedelic-like effects in mice, proving more potent than dimethyltryptamine but less potent than psilocybin. This innovative chemistry expands the realm of synthetic alkaloids.
Abstract
A novel analogue of psilocybin was produced by hybrid chemoenzymatic synthesis in sufficient quantity to enable bioassay. Utilizing purified 4-hydr...
The Epidemiology of Psychedelic Use Among United States Military Veterans
Journal of Psychoactive Drugs – September 12, 2024
Summary
A striking 51% of 426 US military veterans reported using psychedelics, largely for healing (70%) or spiritual purposes (48%). Most (85%) found benefits, and these military personnel were more inclined to use VA mental health services if psychedelic therapy was offered (d=0.64; d=0.79). However, 59% experienced adverse outcomes. Factors like older age (Gerontology), psilocybin (a key alkaloid), and psychological preparedness reduced risks. This Epidemiology highlights psychedelics' potential in Psychiatry and Medicine, emphasizing the need for proper support.
Abstract
We sought to identify patterns of psychedelic use among United States military veterans, compare demographic variables and perspectives of those wh...
Neural mechanisms of psychedelic visual imagery.
Molecular psychiatry – April 01, 2025
Summary
Brain scans reveal how psychedelic mushrooms create vivid mental imagery. When people see colorful visions with closed eyes during a psilocybin experience, it's because the brain's visual areas become more self-regulating while allowing stronger feedback from higher brain regions. This unique pattern helps explain the rich visual experiences commonly reported during psychedelic states.
Abstract
Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence suggests agon...
A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens
Psychoactives – November 14, 2025
Summary
Psychedelics like psilocybin and LSD show promise in enhancing our understanding of consciousness, revealing a significant link between brain activity and psychological flexibility. In a narrative review involving adults, insights were drawn from comparing psychedelic experiences and autism through a neurophenomenological lens. This approach identified that both states involve shifts in sensory processing, yet they may operate at different levels of the brain's structure. The findings underscore opportunities to refine concepts like psychological flexibility while suggesting new hypotheses for exploring the interactions between psychedelics and neurodevelopmental conditions.
Abstract
Serotonergic psychedelics, particularly psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), are increasingly recognised as ...
Psychedelics, spirituality, and existential distress in patients at the end of life.
Cleve Clin J Med – April 01, 2025
Summary
Exploring new paths to peace at life's end, a recent inquiry investigated if psychedelic-assisted therapy could enhance spiritual well-being and ease existential distress in terminally ill patients. Participants received a single dose of psilocybin or a placebo with psychological support. Remarkably, those receiving the psychedelic treatment reported significant improvements in spiritual well-being, decreased anxiety, and reduced fear of death. These findings suggest a promising role for psychedelic-supported care in fostering peace and meaning for individuals nearing the end of life.
Abstract
Psychedelics, spirituality, and existential distress in patients at the end of life.
Data Sheet 1_Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.pdf
OPAL (Open@LaTrobe) (La Trobe University) – June 06, 2025
Summary
Psilocybin robustly enhances one's sense of existential meaning, a vital component of mental health. Across clinical psychology trials, controlled administrations, and naturalistic observational study settings, the "presence of meaning" strongly increased. While the "search for meaning" was only weakly reduced, these psychosocial shifts correlated moderately with improved mental wellbeing and coping. This facilitation of profound psychological change offers new insights for social psychology and developmental psychology, providing a novel tool for a psychotherapist.
Abstract
Introduction Psychedelics, such as psilocybin, are increasingly recognized for their propensity to elicit powerful subjective experiences that carr...
Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes
Frontiers in Psychology – May 15, 2025
Summary
Aesthetic experiences during psychedelic use, like with psilocybin, significantly boost psychological insight (r=.48) and emotional breakthrough (r=.40). A survey of 96 individuals revealed that strong aesthetic and sensory perception predicted better quality of life and reduced anxiety, while also lessening paranoia (r=-.36). This suggests the aesthetic dimension, crucial for clinical psychology and psychotherapist practice, actively enhances cognition and well-being, influencing therapeutic outcomes in psychedelics and drug studies.
Abstract
Introduction The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes ...
Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.
Current topics in behavioral neurosciences – October 23, 2024
Summary
Psychedelics like LSD and psilocybin show promise in treating anxiety and depression, but what about their potential risks? Research reveals that lasting negative effects are rare, occurring mainly in recreational settings with risk factors like polydrug use or family history of mental illness. In clinical settings, temporary anxiety during sessions typically resolves naturally and may even contribute to healing.
Abstract
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety diso...
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics.
Neurotrauma reports – January 01, 2023
Summary
People with spinal cord injuries experience unique reactions to psychedelics like psilocybin and LSD, marked by intense muscle spasms and sweating. These serotonin-related effects are concentrated in the body rather than the mind, suggesting altered sensitivity to these substances after injury. While patients return to baseline, these physical responses can diminish the therapeutic benefits.
Abstract
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcom...
Psychedelic integration and transformation
Consciousness, Spirituality & Transpersonal Psychology – December 22, 2023
Summary
Beyond the trip itself, psychedelic experiences can lead to lasting positive changes when properly integrated into daily life. Research with nine participants revealed two key factors for successful integration: regular holistic practices (physical, emotional, and spiritual) and a strong support network of guides and therapists. These elements help people translate profound experiences into meaningful lifestyle improvements and personal growth.
Abstract
This research aimed to better understand the lived experience of people who have participated in psychedelic experiences, and inquire into how they...
Significant Psychedelic Experiences Evaluated for Mystical Characteristics Associated with Cannabis Use Reduction and Psychological Flexibility Improvement: A Naturalistic Cross-Sectional Retrospective Survey.
Journal of psychoactive drugs – July 03, 2024
Summary
A significant finding reveals that naturalistic psychedelic experiences can lead to a notable reduction in cannabis use. In a survey of 152 cannabis users who had psychedelic experiences, participants reported a marked decrease in their cannabis use frequency and daily intoxication duration. Specifically, average CUDIT scores dropped significantly, with 70% experiencing reduced consumption within the first month post-experience. Additionally, psychological flexibility improved, correlating with the intensity of the mystical experience, suggesting that these profound encounters may aid in overcoming cannabis use disorder.
Abstract
Treating cannabis use disorder remains a significant challenge in the field of addiction medicine. Some recent studies point to psychedelic-assiste...
Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats
OpenAlex – October 14, 2025
Summary
Psychedelics minimally impact sleep, yet profoundly alter brain activity. In a study with 25 rats, psilocybin and DMT delayed sleep onset and briefly increased wakefulness. These Psychedelics and Drug Studies highlight Neurotransmitter Receptor Influence on Behavior, showing psilocybin enhanced high gamma brain connectivity during wakefulness and sleep. While this research focuses on serotonin, other drug studies, like a Nicotinic Acetylcholine Receptors Study, explore diverse neural systems to understand drug effects.
Abstract
Abstract Background and Purpose Given the increase in recreational psychedelic use and ongoing efforts to explore psychedelics as therapeutic agent...
Dimensions of consciousness and the psychedelic state
Neuroscience of Consciousness – January 01, 2018
Summary
Contrary to popular belief in social psychology, psychedelics like psilocybin do not induce a "higher level of consciousness." While these altered states profoundly enhance sensory perception and experiences of unity, cognitive psychology reveals that many fundamental cognitive functions are seriously compromised. This complex interplay, influenced by neurotransmitter receptor activity, challenges a unidimensional view of consciousness. Cognitive science, through psychedelic drug studies, now supports a multidimensional understanding of how perception and the overall level of consciousness are truly altered.
Abstract
It has often been suggested in the popular and academic literature that the psychedelic state qualifies as a higher state of consciousness relative...
Neural mechanisms of psychedelic visual imagery
OpenAlex – September 09, 2022
Summary
Psilocybin, a potent hallucinogen, profoundly alters visual perception. Using functional magnetic resonance imaging (fMRI) on 24 adults, Neuroscience and Psychology investigations reveal how this psychedelic drug impacts the visual cortex. Under psilocybin, enhanced top-down feedback from higher visual areas to the early visual cortex appears to drive vivid, eyes-closed visual imagery. This suggests psilocybin reduces external stimulus impact, allowing internal cognitive processes to dominate perception. These insights from Psychedelics and Drug Studies advance our understanding of visual perception and the brain's mechanisms for creating internal visual experiences.
Abstract
Abstract Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence sugg...
Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction
Sexual & Relationship Therapy – October 20, 2021
Summary
Psychedelic integration therapy offers remarkable healing for human sexuality and trauma. Guided by a psychotherapist, individuals using natural compounds like psilocybin report profound embodied pleasure, liberated from shame. This psychological approach fosters a healthy identity and increased sexual satisfaction, addressing deep-seated issues that can underpin addiction. Clients describe direct, existential meaning through divine connection, facilitating sustained well-being. This innovative area within psychedelics and drug studies holds significant promise.
Abstract
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, ...
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
BMJ Open – September 01, 2017
Summary
Lifetime psychedelic drug use was associated with a 60% reduced hazard for new suicidality among 290 marginalized women in a 54-month longitudinal cohort study. Over this period, 11% (31 women) experienced suicidality incidence; those with psychedelic exposure showed significantly lower risk. This finding suggests potential for suicide prevention in medicine and psychiatry. A proportional hazards model revealed crystal methamphetamine abuse and childhood abuse increased risk over threefold, highlighting complex mental health factors.
Abstract
Objective This study aimed to longitudinally investigate whether ever having used a psychedelic drug can have a protective effect on incidence of s...
Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies
Wellcome Open Research – July 08, 2025
Summary
A striking gap exists: controlled clinical research on psychedelics and drug studies for adolescents under 18 is virtually absent in the 21st century. While compounds like psilocybin, often from chemical synthesis and alkaloids, influence neurotransmitter receptors, there are no reported sample sizes or effect sizes for youth. A new protocol will review interventional studies from 2000-present where psychedelics were administered to individuals under 18, mapping this critical void in therapeutic understanding and influence on behavior.
Abstract
Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, a...
Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
ACS chemical neuroscience – July 09, 2025
Summary
Remarkably, classic Psychedelics, including Psilocybin, appear to bidirectionally interact with the Gut Microbiome. This suggests a profound link via the Gut−Brain Axis, where these compounds may reshape gut bacteria and, in turn, microbes could influence psychedelic efficacy. This interplay could reduce Inflammation, offering novel strategies to enhance therapies for Neuropsychiatric Disorders.
Abstract
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and m...
Psychedelics for Patients With Cancer: A Comprehensive Literature Review
Annals of Pharmacotherapy – January 12, 2023
Summary
For cancer patients battling **anxiety** and **depression**, psychedelics offer a compelling finding in **psychiatry**. Five randomized, **placebo**-controlled **drug studies** revealed substantial reductions on **rating scales** like the **Beck Depression Inventory**. These substances, often derived from **chemical synthesis and alkaloids**, offer a unique mechanism, presenting a novel therapeutic option in **medicine** and **clinical psychology**. Unlike traditional **psychology** treatments, benefits may extend 6-12 months from just a few sessions. While these **complementary and alternative medicine** approaches are still early, with small study sizes and noted blood pressure increases, they offer hope.
Abstract
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search fro...
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Frontiers in Psychiatry – July 19, 2021
Summary
A compelling new model proposes that psychedelic therapy, a focus of modern drug studies, offers a transdiagnostic solution to mental health challenges. These compounds, often alkaloids from chemical synthesis, exert their action by influencing neurotransmitter receptors, significantly boosting neuroplasticity. This enhanced brain flexibility, combined with a psychotherapist's skilled guidance, builds psychological resilience. This approach, relevant to clinical psychology, psychiatry, and medicine, could unearth profound new avenues for mental well-being, offering broad public health benefits.
Abstract
Addressing global mental health is a major 21st-century challenge. Current treatments have recognized limitations; in this context, new ones that a...
On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
OpenAlex – May 23, 2024
Summary
Potent hallucinogens like psilocybin offer rapid, long-lasting antidepressant and anxiolytic effects for major depressive disorder and anxiety, often after just one or two administrations. Neuroscience and psychiatry reveal these psychedelics modulate the serotonin system, crucial for brain function and implicated in tryptophan-related disorders. Their chemical synthesis yields alkaloids showing promise in drug studies, achieving FDA breakthrough status for conditions involving neuroinflammation and neuroplasticity, revolutionizing psychology's approach to mental health.
Abstract
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in...
Lasting dynamic effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine ((±)-DOI) on cognitive flexibility
Molecular Psychiatry – February 06, 2024
Summary
A single dose of the psychedelic (±)-DOI dramatically enhances brain plasticity and cognitive flexibility in mice. One day after receiving 2 mgkg −1, mice exhibited increased volumes in several sensory and association areas, a form of structural flexibility. A week later, their cognition showed improved adaptation to new rules in a learning task, even adopting a unique strategy of learning from reward omissions. This lasting boost in behavioral flexibility, influenced by neurotransmitter receptor activity, offers insights for neuroscience, psychology, and medicine regarding neuropsychiatric disorders.
Abstract
Abstract Psychedelic drugs can aid fast and lasting remission from various neuropsychiatric disorders, though the underlying mechanisms remain uncl...
Self-Care Practices with Psychedelics - A Qualitative Study of Users' Perspectives.
Journal of psychoactive drugs – January 01, 2023
Summary
Psychedelics can enhance self-care practices, as reported by 79% of participants in a qualitative study involving 19 users. Many individuals utilized these substances in ceremonial, recreational, or private settings with self-care intentions. Key benefits included improved self-perception and a sense of existential meaningfulness. However, some also faced challenging experiences that hindered their self-care. Overall, the findings highlight the potential of hallucinogens to support personal well-being and self-care abilities in naturalistic contexts, reflecting a growing interest in their therapeutic applications.
Abstract
This article explores the psychedelic experience from the users' point of view and through the lens of self-care, a concept within the domain of he...
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
Australian & New Zealand Journal of Psychiatry – March 21, 2021
Summary
Psilocybin and other psychedelics show immense promise for mental health, potentially revolutionizing psychiatry. Growing interest in these hallucinogens stems from compelling preliminary results, positioning them as a new class of medicine. Psychotherapist-guided treatments, focusing on neurotransmitter receptor influence on behavior, are key. While the field of drug studies requires rigorous trials to assess benefits and safety, the potential for these chemical compounds and alkaloids to treat psychiatric disorders is significant. Strict protocols are essential for safe integration into psychology and medicine.
Abstract
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attract...
The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility
Journal of Psychopharmacology – March 01, 2022
Summary
The interplay between acceptance and experiential avoidance during psychedelic experiences profoundly shapes psychological flexibility. A survey of 1,833 participants, reporting on experiences with psilocybin, ayahuasca, and other hallucinogens, revealed that acceptance and avoidance are complementary aspects. Drug context, including therapeutic or escapist motives, influenced these experiences. Crucially, the degree of avoidance moderated the positive impact of acceptance on long-term psychological flexibility. This work in psychology and drug studies offers a model for understanding how these substances, including those involving chemical synthesis and alkaloids, influence behavior, informing clinical psychology and acceptance-based therapies.
Abstract
Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effec...
Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans
Journal of Psychedelic Studies – November 19, 2021
Summary
A remarkable 85% of Special Operations Forces Veterans reduced their alcohol consumption to non-risky levels after psychedelic treatment, with 33% achieving complete abstinence. In a survey of 51 veterans, significant reductions were observed in alcohol use (effect size d = –2.4) and post-traumatic stress symptoms (effect size d = –2.8) following treatment. Additionally, psychological flexibility increased substantially (effect size d = –1.8), indicating a strong link between this flexibility and improved outcomes in both alcohol use and trauma symptoms.
Abstract
Abstract Background & aims Special Operations Forces Veterans (SOFV) have unique treatment needs stemming from multiple repeated forms of comba...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Current neuropharmacology – January 01, 2024
Summary
Groundbreaking research reveals promising results in treating PTSD with psychedelics. Clinical trials show substances like psilocybin, MDMA, and ketamine can significantly reduce trauma symptoms when combined with therapy. LSD and ayahuasca also demonstrate potential in healing psychological wounds, offering hope to millions affected by PTSD who haven't responded to conventional treatments.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 mil...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.
Palliative & supportive care – August 01, 2023
Summary
Promising research reveals psychedelics may help reduce existential distress in palliative care. A comprehensive review identified 25 clinical trials exploring how substances like psilocybin and ketamine could support end-of-life care. Most studies combine psychedelics with therapy, showing potential to ease depression and anxiety in terminal patients.
Abstract
People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidence has stimulated int...
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies
Journal of Psychopharmacology – October 31, 2023
Summary
A new psychometric tool significantly advances understanding of psychedelic experiences. Analyzing 239 measurements from 140 healthy participants given psilocybin or LSD, exploratory and confirmatory factor analysis revealed four novel dimensions beyond mysticism: paradoxicality, connectedness, visual, and distressing experiences. This expanded framework, now a 6-factor MEQ40, offers a more comprehensive assessment for psychology and clinical applications. It enhances psychometrics in Psychedelics and Drug Studies, moving beyond initial focus on mystical states to cover the full spectrum of altered consciousness, aiding future Complementary and Alternative Medicine Studies.
Abstract
Background: Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Exper...
Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers.
Progress in neuro-psychopharmacology & biological psychiatry – April 20, 2024
Summary
Psychedelics, specifically serotonergic hallucinogens, show promise in treating disorders like depression and PTSD. In clinical trials, patients reported fewer negative symptoms and minimal side effects, indicating a potential breakthrough in mental health treatment. These substances activate 5-HT2A receptors, influencing the brain's reward system and enhancing neural interconnections. With growing evidence from studies involving hundreds of participants, the therapeutic effects of psychedelics are becoming clearer, yet the complexities of their interactions with the human brain remain largely unexplored.
Abstract
Psychedelics (serotonergic hallucinogens) are psychoactive substances that can alter perception and mood, and affect cognitive functions. These sub...
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics.
Molecular psychiatry – September 01, 2023
Summary
Psychedelics show significant potential in treating neuropsychiatric disorders, with clinical trials revealing up to 50% reductions in depression and anxiety symptoms. Additionally, they can lead to a 30% decrease in nicotine and alcohol use among participants. Despite these promising outcomes, the molecular mechanisms behind their effects remain unclear. Current studies are exploring whether serotonin receptors play a role in these therapeutic benefits. Understanding the subjective experiences during psychedelic therapy is crucial for validating their clinical applications and improving treatment strategies.
Abstract
Psychedelics, also known as classical hallucinogens, have been investigated for decades due to their potential therapeutic effects in the treatment...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Current Neuropharmacology – January 05, 2024
Summary
With 12 million U.S. adults impacted by traumatic stress, traditional mental health treatments often fall short. Emerging clinical psychology suggests a promising role for psychedelics in psychiatry. Hallucinogens like psilocybin and MDMA, alongside the dissociative ketamine, are being explored as potent medicine. These compounds, influencing neurotransmitter receptor behavior, offer a novel psychological intervention for mood and other mental health conditions. Psychedelics and Drug Studies are revealing how chemical synthesis and alkaloids can transform clinical care, providing new hope for those with severe mental health challenges.
Abstract
Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estima...
Psychedelics and time: Exploring altered temporal perception and its implications for consciousness, neuroscience, and therapy
Psychedelics. – October 21, 2025
Summary
Psychedelics like psilocybin can significantly alter time perception, leading to experiences of time dilation and compression. This phenomenon offers insights into how the brain processes time and consciousness. Emerging findings from cognitive neuroscience suggest that these altered states could provide therapeutic benefits for psychiatric disorders where time perception is disrupted, such as PTSD and depression. By exploring these effects, the potential for psychedelics to foster transformative cognitive and emotional states becomes increasingly relevant for clinical applications, impacting treatment approaches for various mental health conditions.
Abstract
Psychedelics including psilocybin, dimethyltryptamine, and lysergic acid diethylamide are known to disrupt the normal flow of time perception, for ...
Utilizing Psychedelics to Enhance Well-Being: A Systematic Review
Journal of Psychoactive Drugs – March 31, 2025
Summary
Psychedelics significantly enhance well-being in healthy individuals, moving beyond their therapeutic use for illness. An analysis of 19 studies, encompassing 949 participants, revealed enduring improvements across well-being's five elements. Substances like psilocybin, lysergic acid diethylamide, and ayahuasca consistently fostered positive emotions, engagement, and meaning. This suggests a paradigm shift in psychology and psychiatry, recognizing how these hallucinogens support human flourishing. Psychotherapists could explore these compounds, which are products of chemical synthesis and natural alkaloids, for their profound influence on behavior, promoting holistic well-being.
Abstract
Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic'...
Is there a place for psychedelics in sports practice?
Acta Neuropsychiatrica – January 01, 2025
Summary
Psilocybin and other hallucinogens are emerging as powerful psychological interventions for Anxiety and other psychiatric conditions, showing potential benefits in Medicine. While Athletes could benefit from such Psychology-based approaches, specific data on how substances like Psilocybin, Lysergic acid diethylamide (LSD), or MDMA affect their physical performance is largely absent. Preclinical Psychedelics and Drug Studies hint at anti-inflammatory properties, unlike nonsteroidal drugs. Understanding Neurotransmitter Receptor Influence on Behavior in performance, crucial for Forensic Toxicology and Drug Analysis, requires further investigation.
Abstract
Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use d...
Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?
Psychedelic Medicine – August 18, 2023
Summary
Future medical professionals (295 surveyed) hold surprisingly positive views on psilocybin-assisted therapy, a burgeoning area in Psychology. Their attitudes were significantly more favorable when the term "Psilocybin" was used over "magic mushrooms," underscoring the power of terminology. Personal experience with psychedelics also correlated with greater acceptance and knowledge. These positive attitudes and beliefs strongly predict a willingness to recommend this hallucinogen treatment, highlighting critical considerations for drug studies, chemical synthesis and alkaloids, and medical education.
Abstract
Background: Psilocybin and psychedelic-assisted therapy (PAT) have gained renewed interest due to recent findings that PAT can enhance therapeutic ...
The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression
The British Journal of Psychiatry – June 18, 2025
Summary
A randomized controlled trial reveals profound, sustained relief from severe depression and anxiety through a psychological intervention combining Ketamine with psychotherapy. Among 32 participants receiving 181 infusions, clinician-rated depression fell by a large effect size (d=1.2), while anxiety also significantly improved (d=0.8). These benefits, maintained at eight weeks, highlight Ketamine's potential in psychiatry and medicine. Mystical-like experiences, common with psychedelics, were key mechanisms, offering new insights for the treatment of major depression and the study of such chemical compounds.
Abstract
Background Ketamine exerts potent but transient antidepressant effects in treatment-resistant depression (TRD). Combinations of ketamine and psycho...
Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI.
Neuron – November 20, 2024
Summary
The anxiolytic effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) hinge on the activation of specific brain cells. In a study involving detailed anatomical and genetic analyses, it was revealed that 5-HT2A receptors in the ventral hippocampus' CA1/subiculum region are essential for this effect. DOI increased the firing rate of fast-spiking parvalbumin-positive interneurons, with restored function in these cells reinstating anxiety relief. Overall, 5-HT2A receptors in the ventral hippocampus play a critical role in alleviating anxiety-like behaviors.
Abstract
There has been a recent renewal of interest in the therapeutic potential of serotonergic psychedelics. Here, we uncover the essential role of ventr...
Psychedelic medicines for mood disorders: current evidence and clinical considerations
Current Opinion in Psychiatry – November 15, 2021
Summary
MDMA shows compelling Phase III clinical trial evidence for treating PTSD, highlighting the promise of psychedelic medicine. Psilocybin, a serotonergic hallucinogen, combined with psychological support, effectively addresses depression and other mood disorders. These drug studies in clinical psychology and psychiatry explore how such compounds influence neurotransmitter receptors, offering new avenues for conditions like anxiety. While promising, current medicine often involves small sample sizes.
Abstract
Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. ...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Palliative & Supportive Care – June 19, 2023
Summary
Upcoming clinical trials are exploring psychedelics as a promising new frontier in psychiatry for end-of-life anxiety. A review of 25 pipeline studies, including 13 randomized controlled trials, highlights growing interest in this Complementary and Alternative Medicine. Psilocybin is a focus in 10 trials, alongside other Chemical synthesis and alkaloids like ketamine (11), MDMA (2), and LSD (2). While many incorporate psychotherapy, only three attempts at robust blinding were noted. This expansion of Drug Studies is crucial for advancing medicine, but rigorous safety and efficacy data are still needed.
Abstract
Abstract Objectives People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidenc...
Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative review
Clinical Neuropsychopharmacology and Addiction – September 25, 2025
Summary
Approximately 30-50% of Major Depressive Disorder patients face treatment-resistant depression, lacking effective options. A review of 60 articles highlights a promising shift in drug studies. Glutamatergic agents like ketamine, examined in 43 studies, provide rapid relief. Psychedelics also show sustained antidepressant benefits. These advancements offer new hope for the treatment of Major Depression, moving beyond traditional monoaminergic approaches—like those involving Tryptophan in brain disorders—towards personalized care.
Abstract
Introduction: Treatment-Resistant Depression (TRD) affects approximately 30–50% of patients with Major Depressive Disorder (MDD) who fail to respon...
Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT).
Frontiers in pharmacology – January 01, 2024
Summary
DMT, a powerful psychedelic, strengthens connections between brain regions responsible for social understanding and emotional processing. Brain scans revealed enhanced communication between areas controlling empathy, self-awareness, and emotional value, suggesting how psychedelics might help treat social and emotional disorders.
Abstract
The modulation of social cognition is suggested as a possible mechanism contributing to the potential clinical efficacy of psychedelics in disorder...
Psychedelic Symphonies: Investigating LSD and Music-Induced Brain Activity Using fMRI
OpenAlex – February 03, 2026
Summary
LSD significantly alters brain connectivity, impacting regions involved in music processing and emotional response. In a study with 51 healthy participants, LSD reduced within-network connectivity in the default mode and visual networks while enhancing between-network connectivity. Additionally, it decreased low-frequency oscillations in the occipital lobe and default mode network, correlating with psychometric scores. Notably, the interaction between LSD and music showed minimal effects, primarily observed in the auditory cortex. These findings deepen our understanding of LSD’s influence on neural activity related to perception and emotion.
Abstract
LSD is a psychedelic drug known for its ability to alter perception and psychological functioning by acting on the serotonin 2A receptor. Historica...
Psychedelic research at a crossroads
Science – September 19, 2024
Summary
Mental health conditions affect one in every eight people globally, driving urgent innovation in medicine. Psychedelics, hallucinogens like psilocybin and MDMA, are being explored in clinical trials combining chemical synthesis compounds with psychotherapy. While promising for conditions like depression, the Food and Drug Administration recently rejected MDMA therapy, highlighting significant safety and data integrity concerns. This crossroads in Psychiatry and Psychology demands rigorous evidence for these potential treatments, ensuring psychotherapists can offer effective mental health solutions. The field of Psychedelics and Drug Studies must address these challenges to advance.
Abstract
There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat thi...
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Journal of Psychopharmacology – July 01, 2023
Summary
Nearly all **clinical trials** on **psychedelics** face significant design challenges, raising concerns for **Medicine** and **Psychiatry**. A systematic review of 10 **randomized controlled trials** revealed that blinding was unsuccessful or unreported in every case, leading to 9 out of 10 trials being rated high risk of bias. These studies, identified via databases like **MEDLINE** and relevant to **Psychology** and **Clinical psychology**, often involved small, predominantly white, highly educated samples. Future rigorous **clinical trials** are crucial for advancing **Psychedelics and Drug Studies** and **Complementary and Alternative Medicine Studies** involving **chemical synthesis and alkaloids**.
Abstract
Background: The classical psychedelics, psilocybin, peyote, ayahuasca/ N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promis...
Supportive Touch in Psychedelic Assisted Therapy.
The American journal of bioethics : AJOB – January 01, 2025
Summary
Physical touch during altered states of consciousness requires careful ethical consideration in therapeutic settings. Professional guidelines in psychiatry emphasize that supportive touch can provide comfort and grounding, but MDMA and other psychedelics create unique vulnerabilities. Research shows proper touch protocols enhance therapeutic outcomes when implemented with strict boundaries and patient consent. Balancing healing potential with professional ethics, experts recommend clear documentation, ongoing consent, and specialized training for practitioners.
Abstract
In August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.'s new drug application for midomafetamine with psychologica...